11 -8 (82) 2025 - Yitmasova T.D., Obloqulov A.R. - COMPARATIVE ASSESSMENT OF THE INITIAL STATE OF LIVER FIBROSIS IN TUBERCULOSIS AND CHRONIC VIRAL HEPATITIS COINFECTION

COMPARATIVE ASSESSMENT OF THE INITIAL STATE OF LIVER FIBROSIS IN TUBERCULOSIS AND CHRONIC VIRAL HEPATITIS COINFECTION

Yitmasova T.D. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Obloqulov A.R. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Usmonov I.K. - Republican specialized phthisiatry and pulmonology scientific and practical medical center

Resume

Coinfection with tuberculosis (TB) and chronic viral hepatitis (CVH) is a serious problem leading to the rapid progression of liver disease. The study aimed to comparatively evaluate the degree of liver fibrosis in patients with TB and CVH coinfection versus patients with CVH only, prior to the initiation of anti-tuberculosis therapy. The study included 59 coinfected patients (main group) and 30 patients with only CVH (control group). The degree of liver fibrosis was assessed using the non-invasive "FibroTest/FibroMax" method according to the METAVIR scale. The results revealed significantly more pronounced liver fibrosis in coinfected patients: advanced fibrosis stages (F3-F4) were significantly more common in this group compared to the control group (p<0.01). In conclusion, the presence of TB infection acts as an independent factor that accelerates liver fibrogenesis against the background of chronic viral hepatitis. This necessitates a thorough assessment of the liver status in coinfected patients before starting treatment

Keywords: tuberculosis, chronic viral hepatitis, coinfection, liver fibrosis, FibroTest, comparative analysis

First page

58

Last page

62

For citation:Yitmasova T.D., Obloqulov A.R., Usmonov I.K. - COMPARATIVE ASSESSMENT OF THE INITIAL STATE OF LIVER FIBROSIS IN TUBERCULOSIS AND CHRONIC VIRAL HEPATITIS COINFECTION//New Day in Medicine 8(82)2025 58-62 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

1. World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024.
2. World Health Organization. Global hepatitis report 2024. Geneva: WHO; 2024.
3. Choi, J. C., & Ihm, J. S. Clinical characteristics of chronic hepatitis B and tuberculosis comorbidity. Clinical and Molecular Hepatology, 2013, 19(2), 164-168.
4. Umarova, A. A., & Alimov, A. V. The course of chronic viral hepatitis B in patients with pulmonary tuberculosis in the endemic region. Journal of Problems of Biology and Medicine, 2021, 2(127), 133-136.
5. Rockey, D. C., & Bissell, D. M. Noninvasive measures of liver fibrosis. Hepatology, 2006, 43(S1), S113-S120.
6. Schuppan, D., & Afdhal, N. H. Liver cirrhosis. The Lancet, 2008, 371(9615), 838-851.
7. Mihm, S. Hepatitis C virus and transforming growth factor-β in the liver. Journal of Gastroenterology and Hepatology, 2001, 16(8), 838-842.
8. Hussain, R., Shirin, M., & Dockrell, H. M. Cytokine profiles in tuberculosis: a systematic review. International Journal of Tuberculosis and Lung Disease, 2007, 11(11), 1152-1165.
9. Bravo, A. A., Sheth, S. G., & Chopra, S. Liver biopsy. New England Journal of Medicine, 2001, 344(7), 495-500.
10. Poynard, T., Morra, R., Halfon, P., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology, 2007, 7(1), 40.
11. Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 2006, 174(8), 935-952.
12. Ivanova D.A., Borisov S.E., Ryzhova L.N. Risk factors and structure of drug-induced liver injury in tuberculosis patients. Therapeutic Archive, 2019, 91(11), 49-55.

    file

    download